This is the complete third paragraph of the PR:
Post# of 151654
"If approved by the FDA, patients in this trial will be randomized in a 1:1 ratio to receive up to four doses of (<<700 mg leronlimab with standard of care>>

I've added my own parentheses/etc to indicate my impression of the sentence.
This is like the math rules: 5 + 3 x 4 = 60, not 32, because by rule, you perform the multiplication first, then the addition.
There is no SOC which involves a 30 minute IV infusion once per week. SOC will continue for all patients, with the usual established or customized dosing, separate from administering LL or placebo. IMO.

